688767.SHG Hangzhou Biotest Biotech Co Ltd
- Market cap
- CNY 5.77B
- P/E
- 429.6x
- P/B
- 2.47x
- ROE
- -1.5%
- Dividend yield
- 2.77%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688767.SHG undervalued?
Graham numberThe Graham number of Hangzhou Biotest Biotech Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hangzhou Biotest Biotech Co Ltd fundamental analysis
No fundamental analysis for Hangzhou Biotest Biotech Co Ltd yet.
Hangzhou Biotest Biotech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hangzhou Biotest Biotech Co Ltd
Hangzhou Biotest Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of in vitro diagnostic reagents in China and internationally. The company offers point-of-care testing rapid diagnostic reagents for drug abuse, infectious disease, fertility health, tumor market/oncology, cardiology market, veterinary, inflammation, and other testing. It also provides microfluidic immunofluorescence analysis systems; and Dia…
Full company profileHangzhou Biotest Biotech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hangzhou Biotest Biotech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 122M | 180M | 209M | 865M | 1.82B | 1.90B | 442M | 559M | 448M | 429M |
| Gross Profit | 42.2M | 64.6M | 87.2M | 623M | 1.11B | 961M | 173M | 273M | 448M | 202M |
| Operating Income | 4.26M | 22.5M | 32.2M | 513M | 967M | 914M | 117M | 193M | 50.1M | 441K |
| EBITDA | 8.21M | 28.0M | 38.3M | 520M | 978M | 922M | 141M | 218M | 70.5M | -46.9M |
| Net Income | 4.03M | 18.9M | 28.2M | 435M | 834M | 774M | 107M | 170M | 46.8M | -33.1M |
| EPS | 0.04 | 0.17 | 0.25 | 3.89 | 6.87 | 5.18 | 0.71 | 1.15 | 0.32 | -0.22 |
| Balance Sheet | ||||||||||
| Total Assets | 128M | 155M | 210M | 634M | 2.43B | 2.75B | 2.58B | 2.60B | 2.54B | 2.41B |
| Total Liabilities | 47.9M | 56.5M | 84.5M | 191M | 323M | 189M | 159M | 190M | 168M | 261M |
| Shareholders' Equity | 80.3M | 98.9M | 127M | 444M | 2.11B | 2.56B | 2.42B | 2.41B | 2.37B | 2.14B |
| Cash & Short-term Investments | 8.90M | 16.3M | 13.8M | 261M | 1.73B | 2.04B | 1.91B | 1.65B | 1.48B | 1.25B |
| Total Debt | 20.1M | 20.1M | 32.1M | 11.1M | 12.5M | 7.64M | 589K | 441K | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 7.07M | 21.2M | 25.7M | 446M | 908M | 703M | 131M | 129M | 106M | - |
| Capital Expenditure | 26.4M | 12.7M | 39.5M | 57.7M | 200M | 179M | 56.4M | 245M | 130M | 62.0M |
| Free Cash Flow | -19.3M | 8.50M | -13.8M | 388M | 708M | 524M | 75.0M | -116M | -23.4M | -45.8M |
| Ratios | ||||||||||
| ROE | 5.0% | 19.1% | 22.2% | 98.0% | 39.6% | 30.2% | 4.4% | 7.0% | 2.0% | -1.5% |
| ROA | 3.2% | 12.2% | 13.4% | 68.6% | 34.3% | 28.1% | 4.1% | 6.5% | 1.8% | -1.4% |
| Net Profit Margin | 3.3% | 10.5% | 13.5% | 50.3% | 45.9% | 40.7% | 24.1% | 30.3% | 10.4% | -7.7% |
| Debt to Equity | 0.25x | 0.20x | 0.25x | 0.02x | 0.01x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hangzhou Biotest Biotech Co Ltd dividends
- Dividend yield
- 2.77%
- Forward dividend
- 0.70 CNY
- Payout ratio
- 341.6%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 160M | 1.09 | 341.6% |
| 2024 | CNY 83.6M | 0.57 | 49.3% |
| 2023 | CNY 235M | 1.57 | 220.1% |
| 2022 | CNY 320M | 2.14 | 41.4% |
| 2021 | CNY 20.9M | 0.17 | 2.5% |
| 2020 | CNY 100M | 0.90 | 23.1% |
| 2019 | CNY 1.08M | 0.01 | 3.8% |
| 2018 | 883K | 0.01 | 4.7% |
| 2017 | 610K | 0.01 | 15.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 6, 2025.
Who owns Hangzhou Biotest Biotech Co Ltd
- Insiders 66.00%
- Institutions 1.83%
- Public & others 32.18%
- Shares outstanding 149M
- Free float 59.6M
Hangzhou Biotest Biotech Co Ltd company profile
- Company name
- Hangzhou Biotest Biotech Co Ltd
- Ticker
- 688767.SHG
- ISIN
- CNE1000050H0
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 613
- Fiscal year end
- December
- Address
- No. 27, Tuyi Road, Hangzhou, China, 311100
- Phone
- 86 571 8905 8000
- Website
- biotests.com.cn
About Hangzhou Biotest Biotech Co Ltd
Hangzhou Biotest Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of in vitro diagnostic reagents in China and internationally. The company offers point-of-care testing rapid diagnostic reagents for drug abuse, infectious disease, fertility health, tumor market/oncology, cardiology market, veterinary, inflammation, and other testing. It also provides microfluidic immunofluorescence analysis systems; and Diagpal SE and Diagpal lateral flow readers. In addition, the company engages in investing activities. Its products are used across various medical institutions, judicial testing systems, third-party testing organizations, centers for disease control and prevention (CDC), and private clinics. Hangzhou Biotest Biotech Co.,Ltd. was founded in 2008 and is headquartered in Hangzhou, China.
Hangzhou Biotest Biotech Co Ltd management
6- Mr. Shujiang WuGM & Director · born 1977
- Ms. Miao Miao YuAccounting Supervisor & Financial Director · born 1981
- Mr. Yujie ChenDeputy GM & Director · born 1990
- Mr. Chun Sheng YeDeputy GM & Director · born 1976
- Mr. Qi Jun FeiDeputy GM & Secretary of the Board of Directors · born 1981
- Mr. Chao LiuDeputy General Manager · born 1984